Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID‐19
Cell Proliferation2020Vol. 53(12), pp. e12949–e12949
Citations Over TimeTop 1% of 2020 papers
Qi‐Dong Xia, Yang Xun, Junlin Lu, Yuchao Lu, Yuanyuan Yang, Peng Zhou, Jia Hu, Cong Li, Shaogang Wang
Abstract
The network pharmacological strategy integrates molecular docking to unravel the molecular mechanism of LQC. Akt1 is a promising drug target to reduce tissue damage and help eliminate virus infection.
Related Papers
- → Utilizing network pharmacology to explore potential mechanisms of YiSui NongJian formula in treating myelodysplastic syndrome(2021)15 cited
- → Based on network pharmacology and molecular docking to predict the mechanism of Huangqi in the treatment of castration-resistant prostate cancer(2022)11 cited
- → Network pharmacology-based analysis of Zukamu granules for the treatment of COVID-19(2021)15 cited
- → Network Analyses of Integrated Differentially Expressed Genes in Papillary Thyroid Carcinoma to Identify Characteristic Genes(2019)13 cited
- → Pharmacological Mechanism of Shen Huang Chong Ji for Treating Alzheimer’s Disease Based on Network Pharmacology and Experimental Validation(2022)